Symbient Selected to Develop Fluidic Platform for Implantable Drug Delivery Device

Symbient's internal rapid-prototyping capabilities will allow PKC to reduce development time of the platform by 75% compared to industry standard practices.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
SymbientPD Phamaco Kinesis MBP Device
We selected Symbient for their team's depth of experience in engineering fluidic medical devices that interface with complex electromechanical systems.

Vista, CA (PRWEB) March 25, 2014

Symbient Product Development has been selected by Pharmaco-Kinesis Corporation (PKC) to develop a compact, production-ready fluidic platform for their Metronomic Bio-Feedback Pump (MBP).

The MBP is a development-stage implantable device that monitors and delivers metered quantities of chemotherapy drugs using a custom catheter. Its secure wireless connection enables doctors to individualize treatment by adjusting dosage over the course of chemotherapy. This capability allows the patient to be treated from the comfort of their home instead of having to visit a doctor's office for every dose of medication.

Symbient's senior team of mechanical and bio-engineers are developing the design-for-manufacture of an injection-molded platform with fluidic channels, ports, wells and valves that will integrate with PKC's cutting edge bio-electronic system that is the backbone of the MBP.

"We selected Symbient for their team's depth of experience in engineering fluidic medical devices that interface with complex electromechanical systems. I have found Espir Kahatt, principal product development engineer, and his team to be extremely knowledgeable, friendly and a true pleasure to work with," said Dan Murray, senior mechanical design engineer at PKC.

PKC will benefit from Symbient's internal rapid-prototyping capabilities that enable the engineering team to quickly iterate and complete the design. This process will reduce development time of the platform by 75% compared to industry standard practices. Using its in-house injection molding machines, Symbient will manufacture prototypes that replicate production units which PKC can use to commence pre-clinical and clinical trials on an accelerated schedule.

"We are pleased to partner with such a pioneering company as Pharmaco-Kinesis to develop a critical component of a medical device that will transform the treatment of patients with advanced cancer," said Luke Helm, Director of Business Development at Symbient.

About Symbient: Launched in 2004, Symbient Product Development specializes in the design and engineering of precision injection-molded medical devices, usually intended for volume production. Examples include diagnostic cartridges, sample collection devices, drug delivery platforms, implantable devices, clinical tools, and disposables used in complex laboratory automation systems. The company is ISO 13485 certified and provides complete product development services, from concept design to manufacturing transfer, and a'-la-carte services for specifics phases of a project. Its team of mechanical and biomedical engineers, industrial designers, technicians and machinists create rapid prototypes, prototype molds, and fully-functioning prototypes, resulting in designs that are ready for manufacturing. For more information, please visit http://www.symbientpd.com.


Contact